• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    SELLAS Life Sciences Group, Inc. - Common Stock (NQ:SLS)

    2.870 +0.030 (+1.06%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about SELLAS Life Sciences Group, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About? ↗
    Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover. 
    Via Stocktwits
    News headline image
    Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
    Issued on behalf of GT Biopharma, Inc. 
    From Equity Insider
    Via GlobeNewswire
    News headline image
    These stocks are gapping in today's session ↗
    The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
    Via Chartmill
    Why Is SELLAS Life Sciences Stock Falling Today? ↗
    Via Stocktwits
    News headline image
    SELLAS Life Sciences Stock Has Doubled This Year – Here’s Why Retail Investors Are Bullish ↗
    The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest. 
    Via Stocktwits
    Topics Death
    News headline image
    SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market ↗
    The trial involved combining SLS009 with azacitidine and venetoclax in patients with relapsed or refractory acute myeloid leukemia. 
    Via Stocktwits
    Topics Artificial Intelligence
    News headline image
    10 Health Care Stocks With Whale Alerts In Today's Session ↗
     
    Via Benzinga
    News headline image
    Papa John's Is Not First: Here Are 3 Other Stocks Rocked By Market-Moving Fake News ↗
    Papa John's (PZZA) stock surged from a fake news hoax. It's not the first. See 3 other stocks, like Vinci & Avon, hit by market scams. 
    Via Benzinga
    News headline image
    These stocks are moving in today's after hours session ↗
    Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session. 
    Via Chartmill
    News headline image
    Sellas Life Sciences Stock Jumps Over 7% Premarket: Buzz Builds Ahead Of Weekend Cancer Drug Presentation In Berlin ↗
    The company said its cancer drug SLS009 showed strong preclinical results in T-cell prolymphocytic leukemia, improving survival and reducing tumor burden both alone and in combination with venetoclax. 
    Via Stocktwits
    News headline image
    SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment ↗
    SELLAS said that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference. 
    Via Stocktwits
    News headline image
    Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants ↗
    In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of... 
    Via Stocktwits
    News headline image
    SELLAS Life Sciences Group Inc (NASDAQ:SLS) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Amid Revenue Challenges ↗
    SELLAS Life Sciences (SLS) reported Q2 2025 EPS of -$0.07, beating estimates, with no revenue. Cash position strengthened to $25.3M. Clinical trials progress highlighted, including REGAL Phase 3 AML... 
    Via Chartmill
    News headline image
    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
    EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INDP),(NYSE:CATX),(NASDAQ:SLS),(NASDAQ:AUTL EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Thursday's after hours session: top gainers and losers ↗
    After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
    Via Chartmill
    News headline image
    Top movers in Tuesday's after hours session ↗
    The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today. 
    Via Chartmill
    News headline image
    Wondering what's happening in today's after-hours session? ↗
    As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
    Via Chartmill
    News headline image
    What's going on in today's after hours session ↗
    After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
    Via Chartmill
    News headline image
    These stocks are moving in today's session ↗
    Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
    Via Chartmill
    News headline image
    8 Health Care Stocks Whale Activity In Today's Session ↗
     
    Via Benzinga
    News headline image
    SLS Stock Earnings: SELLAS Life Sciences Gr Beats EPS for Q2 2024 ↗
    SLS stock results show that SELLAS Life Sciences Gr beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    News headline image
    Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
     
    Via Benzinga
    News headline image
    Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
    EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024 ↗
    SLS stock results show that SELLAS Life Sciences Gr missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
    From FN Media Group LLC
    Via GlobeNewswire
    News headline image
    SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023 ↗
    SLS stock results show that SELLAS Life Sciences Gr missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    News headline image
    Dow Falls Over 200 Points; Adobe Shares Plunge ↗
    U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday. The Dow traded down 0.55% to 38,692.43 while the NASDAQ fell 0.90% to 15,982.65. The S&P... 
    Via Benzinga
    Topics Stocks
    News headline image
    Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
    Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
     
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.